Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report)’s stock price gapped up prior to trading on Friday after Guggenheim raised their price target on the stock from $50.00 to $65.00. The stock had previously closed at $33.70, but opened at $34.86. Guggenheim currently has a buy rating on the stock. Spyre Therapeutics shares last traded at $35.76, with a volume of 29,172 shares trading hands.
SYRE has been the subject of several other reports. Wedbush started coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price target for the company. Evercore ISI began coverage on Spyre Therapeutics in a research report on Tuesday, July 16th. They issued an “outperform” rating for the company. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, Spyre Therapeutics has an average rating of “Buy” and an average price target of $46.43.
Get Our Latest Analysis on SYRE
Institutional Inflows and Outflows
Spyre Therapeutics Price Performance
The firm has a market cap of $1.40 billion, a P/E ratio of -0.49 and a beta of 2.92. The company has a fifty day moving average of $29.09 and a 200-day moving average of $30.40.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.04. On average, sell-side analysts expect that Spyre Therapeutics, Inc. will post -3.68 EPS for the current fiscal year.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
See Also
- Five stocks we like better than Spyre Therapeutics
- Ride Out The Recession With These Dividend Kings
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How Technical Indicators Can Help You Find Oversold Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- About the Markup Calculator
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.